PMID- 34337733
OWN - NLM
STAT- MEDLINE
DCOM- 20220304
LR  - 20220304
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 25
IP  - 14
DP  - 2021 Jul
TI  - Liraglutide improves pancreatic islet beta cell apoptosis in rats with type 2 
      diabetes mellitus by inhibiting the IKKepsilon/NF-kappaB pathway.
PG  - 4818-4828
LID - 26395 [pii]
LID - 10.26355/eurrev_202107_26395 [doi]
AB  - OBJECTIVE: The purpose of this study was to explore the effect of liraglutide on 
      pancreatic islet beta cell apoptosis in rats with type 2 diabetes mellitus (T2DM) 
      and the potential mechanisms. MATERIALS AND METHODS: SD rats were randomly 
      divided into control group, model group, and liraglutide groups (200 and 100 
      mug/(kg.d)). Rats were fed with high sugar and high-fat diet for 8 weeks, and then 
      streptozotocin (STZ) 40 mg/kg was intraperitoneally injected to establish T2DM 
      model. After successful modeling, rats in the intervention group were given 
      liraglutide through subcutaneous injection for 6 weeks. The indexes of glucose 
      metabolism and lipid metabolism were measured. Apoptosis of islet beta cells was 
      detected by TUNEL. Western blot and RT-PCR were used to detect the protein and 
      mRNA expression levels of IKK epsilon, NF-kappa B, Bcl-2, Bax, IL-6, and Gal-3 in 
      pancreatic tissue. RESULTS: Compared with the control group, the serum FPG, INS, 
      HOMA-IR, TC, TG, LDL-C, IL-6, islet apoptosis rate, glucagon, the positive 
      expression rate of Gal-3, and body weight in the T2DM group were all 
      significantly increased (p<0.05). However, the levels of insulin, SOD, HDL, and 
      HOMA-beta were notably decreased in the T2DM group in comparison with the control 
      group (p<0.05). Moreover, the mRNA and protein expression levels of IKKepsilon, NF-kappaB, 
      Bax, IL-6, and Bax/Bcl-2 were markedly increased in pancreatic tissue (p<0.05). 
      After liraglutide treatment, these changes were reversed in a dose-dependent 
      manner. CONCLUSIONS: Liraglutide improves pancreatic islet beta cell apoptosis in 
      rats with type 2 diabetes mellitus by inhibiting the IKKepsilon/NF-kappaB pathway.
FAU - Liu, Y-T
AU  - Liu YT
AD  - Department of Endocrinology, Affiliated Ren He Hospital of China Three Gorges 
      University, The Second Clinical Medical College of China Three Gorges University, 
      Yichang, China. huiqiongli@yeah.net.
FAU - He, T
AU  - He T
FAU - Li, H-Q
AU  - Li HQ
FAU - Jiang, P
AU  - Jiang P
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Ikbkg protein, rat)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (NF-kappa B)
RN  - 5W494URQ81 (Streptozocin)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Diabetes Mellitus, Experimental/chemically induced/*drug therapy/metabolism
MH  - Diabetes Mellitus, Type 2/chemically induced/*drug therapy/metabolism
MH  - Hypoglycemic Agents/administration & dosage/chemistry/*pharmacology
MH  - Injections, Intraperitoneal
MH  - Injections, Subcutaneous
MH  - Insulin-Secreting Cells/*drug effects/physiology
MH  - Intracellular Signaling Peptides and Proteins/antagonists & inhibitors/metabolism
MH  - Islets of Langerhans/*drug effects/pathology
MH  - Liraglutide/administration & dosage/chemistry/*pharmacology
MH  - Male
MH  - NF-kappa B/antagonists & inhibitors/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Streptozocin/administration & dosage
EDAT- 2021/08/03 06:00
MHDA- 2022/03/05 06:00
CRDT- 2021/08/02 06:22
PHST- 2021/08/02 06:22 [entrez]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2022/03/05 06:00 [medline]
AID - 26395 [pii]
AID - 10.26355/eurrev_202107_26395 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2021 Jul;25(14):4818-4828. doi: 
      10.26355/eurrev_202107_26395.